Skip to main content

Table 2 Incidence of TEAEs by primary system organ class (safety population, N = 77)

From: Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study

  Combined treatment (IND + GLY) IND alone (IND + placebo) All
Primary system organ class N = 77, n (%) N = 77, n (%) N = 77, n (%)
Number (%) of patients with at least one AE 5 (6.5) 3 (3.9) 8 (10.4)
Investigations 1 (1.3) 2 (2.6) 3 (3.9)
Respiratory, thoracic & mediastinal disorders 2 (1.3) 1 (1.3) 3 (3.9)
Infections & infestations 1 (1.3) 0 1 (1.3)
Musculoskeletal and connective tissue disorders 1 (1.3) 0 1 (1.3)
  1. TEAEs treatment-emergent adverse events, IND indacaterol, IND + GLY indacaterol and glycopyrronium, N or n number of patients, AE adverse event
\